Galmed Pharmaceuticals Ltd reports results for the quarter ended June 30 - Earnings Summary
Galmed Pharmaceuticals Ltd reports results for the quarter ended June 30 - Earnings Summary
Galmed Pharmaceuticals Ltd GLMD.OQ reported quarterly adjusted earnings of $2.86 per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-4.96. The lone analyst forecast for the quarter was for a loss of $3.04 per share.
Reported revenue was zero.
Galmed Pharmaceuticals Ltd's reported EPS for the quarter was $2.32.
The company reported quarterly net income of $1.91 million.
Galmed Pharmaceuticals Ltd shares had fallen by 7.4% this quarter and lost 31.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 2.6% in the last three months.
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."
This summary was machine generated from LSEG data September 4 at 01:15 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Mar. 31 2026 | -3.12 | 2.32 | Beat |
Mar. 31 2026 | -4.08 | 2.32 | Beat |
Sep. 30 2025 | -4.32 | -6.40 | Missed |
Jun. 30 2025 | -4.32 | -5.04 | Missed |